✦ LIBER ✦

Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis

✍ Scribed by Ronan J. Walsh; Sek Won Kong; Yihong Yao; Bahija Jallal; Peter A. Kiener; Jack L. Pinkus; Alan H. Beggs; Anthony A. Amato; Steven A. Greenberg

Book ID: 102752430
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 639 KB
Volume: 56
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.22928

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interleukin-6 and type I interferon–regu

Interleukin-6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositis

✍ Hatice Bilgic; Steven R. Ytterberg; Shreyasee Amin; Kelly T. McNallan; Joseph C. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Abstract ## Objective Up‐regulation of whole blood type I interferon (IFN)–driven transcripts and chemokines has been described in a number of autoimmune diseases. An IFN gene expression “signature” is a candidate biomarker in patients with dermatomyositis (DM). This study was performed to eval

Association of increased interferon-indu

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

✍ Xuebing Feng; Hui Wu; Jennifer M. Grossman; Punchong Hanvivadhanakul; John D. Fi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

Plasminogen activator inhibitor type-1 g

Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-β1-stimulated smooth muscle cells is pp60c-src/MEK-dependent

✍ Rohan Samarakoon; Craig E. Higgins; Stephen P. Higgins; Stacie M. Kutz; Paul J. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

## Abstract Transforming growth factor‐β1 (TGF‐β1) stimulates expression of plasminogen activator inhibitor type‐1 (PAI‐1), a serine protease inhibitor (__SERPIN__) important in the control of stromal barrier proteolysis and cell‐to‐matrix adhesion. Pharmacologic agents that target MEK (PD98059, U0